1-(4,4-dimethyl-cyclohex-1-enyl)-pyrrolidine | 41172-02-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(4,4-dimethyl-cyclohex-1-enyl)-pyrrolidine
• 英文别名: 1-(N-pyrrolidino)-4,4-dimethylcyclohexene；1-(4,4-dimethylcyclohexen-1-yl)pyrrolidine
• CAS: 41172-02-5
• 化学式: C₁₂H₂₁N
• 分子量: 179.305
• InChiKey: GSSRATVPVQOGGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4,4-dimethyl-cyclohex-1-enyl)-pyrrolidine 在 硫酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 6,6-dimethyl-5,6,7,8-tetrahydroquinolin-2(1H)-one
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES
  [FR] COMPOSÉS POUR TRAITER DES MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  这项发明提供了一种新型的Formula α的螺环四氢萘化合物，可以抑制APP的β-分泌酶裂解，并且可用作治疗神经退行性疾病的治疗剂。

  公开号：

  WO2011123674A1
• 作为产物：
  描述：

  4,4-二甲基-2-环己基-1-酮 在 palladium on activated charcoal 氢气 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 20.0h， 生成 1-(4,4-dimethyl-cyclohex-1-enyl)-pyrrolidine
  参考文献：
  名称：

  [EN] COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES
  [FR] COMPOSÉS POUR TRAITER DES MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  这项发明提供了一种新型的Formula α的螺环四氢萘化合物，可以抑制APP的β-分泌酶裂解，并且可用作治疗神经退行性疾病的治疗剂。

  公开号：

  WO2011123674A1

文献信息

• [EN] AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] DERIVES AMIDO ET LEUR UTILISATION COMME INHIBITEURS DE LA 11-BETA-HYDROXYSTEROIDE DESHYDROGENASE DE TYPE 1
  申请人：NOVARTIS AG

  公开号：WO2004065351A1

  公开（公告）日：2004-08-05

  Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.

  化合物的化学式（I）提供了降低哺乳动物细胞内糖皮质激素浓度的药物，特别是降低人类细胞内皮质醇水平的药物。因此，本发明的化合物改善了肌肉和脂肪组织中的胰岛素敏感性，并减少了脂肪组织中的脂解和游离脂肪酸产生。本发明的化合物降低了哺乳动物肝脏内的糖皮质激素浓度，特别是降低了人类肝脏内的皮质醇浓度，从而抑制了肝葡萄糖生成和降低了血浆葡萄糖水平。因此，本发明的化合物可能特别适用于哺乳动物作为降糖药物，用于治疗和预防高血糖和/或胰岛素抵抗等疾病，如2型糖尿病。本发明的化合物还可用于治疗其他与糖皮质激素相关的疾病，如X综合症、血脂异常、高血压和中心性肥胖。此外，本发明还涉及根据本发明的化合物用于制备药物，特别是用于治疗和预防与糖皮质激素相关疾病的药物，通过改善胰岛素敏感性、降低血浆葡萄糖水平、减少脂解和游离脂肪酸产生，以及减少内脏脂肪组织形成。
• A useful α, α′ - annulation reaction of enamines
  作者：Alison J. Frontier、Samuel J. Danishefsky、Gary A. Koppel、Dongfang Meng

  DOI：10.1016/s0040-4020(98)00788-1

  日期：1998.10

  The reactions of a series of enamines generated from a range of cyclic ketones with chloromethyl and iodomethyl vinyl ketone have been studied. The principal products are bridged ring diketones. The four carbon bridge, bearing a 2-oxobutyl function, spans the α and α′ carbons of the original cyclanone. Presumptive evidence as to the pathway of this novel one step bridging annulation is provided.

  研究了由一系列环酮生成的一系列烯胺与氯甲基和碘甲基乙烯基酮的反应。主要产品为桥环二酮。具有2-氧丁基的功能的四碳桥跨越原始环烷酮的α和α'碳。提供了关于这种新颖的一步桥接环空的途径的推定证据。
• Photochemistry of 6-trifluoromethyl-4,4-dimethyl-2-cyclohexenone
  作者：G. Cruciani、P. Margaretha

  DOI：10.1016/s0022-1139(00)83090-0

  日期：1987.10

  The photochemical behaviour of the title compound, newly synthesized in four steps from 4,4-dimethylcyclohexanone, is compared to that of 4,4-dimethyl- and 4,4,6-trimethyl-2-cyclohexenone. All three enones undergo rearrangement to bicyclo[3.1.0]hexan-2-ones and 3-isopropyl-2-cyclopentenones in benzene, t.butanol and acentonitrile, but only the CF3-enone is also reduced to the saturated ketone in the

  比较了由4,4-二甲基环己酮分四个步骤新合成的标题化合物的光化学行为与4,4,2-二甲基和4,4,6-三甲基-2-环己烯酮的光化学行为。所有三个烯酮在苯，叔丁醇和乙腈中均发生重排，生成双环[3.1.0]己-2-酮和3-异丙基-2-环戊烯酮，但只有CF 3-烯酮也被还原为饱和酮。后两种溶剂。
• Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I
  申请人：Coppola Mark Gary

  公开号：US20060205772A1

  公开（公告）日：2006-09-14

  Compounds of the formula (I) provide pharmacological agents which lower intracellular glucocorticoid concentrations in mammals, in particular, intracellular cortisol levels in humans. Therefore, the compounds of the instant invention improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compounds of the invention lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compounds of the instant invention may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compounds of the invention may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compounds according to the invention for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing

  化合物(I)的配方提供了降低哺乳动物细胞内糖皮质激素浓度的药物，特别是降低人类细胞内皮质醇水平的药物。因此，本发明的化合物改善了肌肉和脂肪组织中的胰岛素敏感性，并减少了脂肪组织中的脂解和游离脂肪酸产生。本发明的化合物降低了哺乳动物肝脏中的糖皮质激素浓度，特别是人类肝脏中的皮质醇浓度，从而抑制了肝糖异生并降低了血浆葡萄糖水平。因此，本发明的化合物在哺乳动物中可能特别有用作为降糖药物，用于治疗和预防与高血糖和/或胰岛素抵抗有关的疾病，例如2型糖尿病。本发明的化合物还可用于治疗其他与糖皮质激素相关的疾病，例如综合征X、血脂异常、高血压和中心性肥胖。此外，本发明还涉及使用根据本发明的化合物制备药物，特别是用于改善胰岛素敏感性、降低血浆葡萄糖水平、减少脂解和游离脂肪酸产生，并通过降低糖皮质激素浓度来降低肝糖异生的药物，用于治疗和预防糖皮质激素相关疾病。
• COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES
  申请人：Clark Christopher T.

  公开号：US20120065195A1

  公开（公告）日：2012-03-15

  The invention provides novel spirotetrahydronaphthalene compounds of Formula α that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

  本发明提供了一种新型的螺四氢萘酚化合物，其化学式为α，可以抑制β-分泌酶对APP的切割，并且可用作治疗神经退行性疾病的治疗剂。